China
Africa
Explore chapters and articles related to this topic
Cancer Drugs and Treatment Formulations for Women-Associated Cancers
Published in Shazia Rashid, Ankur Saxena, Sabia Rashid, Latest Advances in Diagnosis and Treatment of Women-Associated Cancers, 2022
Reetika Arora, Pawan K. Maurya
Uterine cancer was shown to be responsible for 7% of all cancer cases and 4% of female cancer deaths [5]. Uterine cancer affects one out of every 36 women. It is cancer of the uterine lining, the endometrium, which makes it more prevalent than cervical or ovarian malignancies. Unlike cervical cancer, it is not a gynaecological malignancy caused by HPV. Hormonal imbalances, notably estrogen, play a key role in the development of uterine cancer, which, like breast cancer, feeds on estrogen. Taking estrogen after menopause, birth control pills, a higher number of menstrual cycles (over a lifetime), previous or current use of tamoxifen for breast cancer, infertility, obesity and having polycystic ovarian syndrome are all factors that can alter hormone levels and increase the risk of uterine cancer [5].
Cancer
Published in Jahangir Moini, Matthew Adams, Anthony LoGalbo, Complications of Diabetes Mellitus, 2022
Jahangir Moini, Matthew Adams, Anthony LoGalbo
Uterine cancer is also known as endometrial cancer. It originates from the glandular epithelium of the uterus. It is the most common gynecological cancer, and occurs in the fifth or sixth decade of life. Uterine cancer is diagnosed via biopsy and occurs most often in developed countries that have high-fat diets. In a variety of studies, diabetes has been linked to higher risk for uterine cancer, but there has been some controversy over this relationship.
Cancer
Published in Sally Robinson, Priorities for Health Promotion and Public Health, 2021
Common symptoms of uterine cancer include abnormal or unusually heavy bleeding, especially post menopausevaginal discharge
Long-term risk of uterine malignancies in women with uterine fibroids confirmed by myomectomy: a population-based study
Published in Journal of Obstetrics and Gynaecology, 2022
Recent studies suggest that leiomyosarcomas do not arise from the malignant change of fibroids. However, several studies have shown that having a history of uterine fibroids is related to uterine cancer (Brinton et al. 2005; Fortuny et al. 2009; Wise et al. 2016; Johnatty et al. 2020). In previous studies, uterine cancer was diagnosed soon after the diagnosis of uterine fibroids; thus, there is a possibility that the existing uterine cancer could be mistaken for uterine fibroids. (Brinton et al. 2005; Wise et al. 2016). Some fibroids were based on self-reports, and some fibroids were not diagnosed prior to diagnosis of endometrial cancer. (Johnatty et al. 2020). Due to these problems, our study was conducted with patients who had uterine fibroids confirmed by myomectomy. Since no studies have yet investigated the long-term risk of uterine cancer in patients with uterine fibroids confirmed by myomectomy, we conducted this study to determine whether uterine fibroids confirmed by myomectomy are a risk factor for uterine cancer.
Phase-specific and lifetime economic burden of cervical cancer and endometrial cancer in a commercially insured United States population
Published in Journal of Medical Economics, 2021
Ruchit Shah, Shelby Corman, Anuj Shah, Nehemiah Kebede, Chizoba Nwankwo
Cancers of the cervix and the uterine corpus are two of the most common malignancies of the female reproductive system in the United States (US). In 2019, cervical and uterine cancers accounted for an estimated 12% and 57%, respectively, of newly diagnosed gynecological cancers in the US1. While the widespread adoption of screening has contributed to a significant decline in the incidence of cervical cancer, the number of patients diagnosed with advanced disease has continued to rise2. A large proportion of cervical cancer patients (52%) present with regional or distant disease at diagnosis3. This in turn has contributed to an estimated 5-year survival rate of 66.1% among cervical cancer patients3. Adenocarcinomas of the endometrium are the most common gynecological cancers, accounting for over 90% of uterine cancer cases1. Unlike patients diagnosed with other gynecological cancers, a majority of endometrial cancer patients (67%) are diagnosed at an early stage, resulting in an 81.2% 5-year survival rate4. Treatment of cervical and endometrial cancer requires consideration of the type and stage of cancer and the desire to maintain fertility. These treatment considerations coupled with the higher overall survival in this patient population in turn affect the accumulation of health care costs over the patient’s lifetime.
The current clinical approach to newly diagnosed uterine cancer
Published in Expert Review of Anticancer Therapy, 2020
Olga T. Filippova, Mario M. Leitao
Uterine cancer is the most common gynecologic malignancy, accounting for approximately 50% of all diagnosed gynecologic malignancies in the United States [1]. It is also the fourth most common cancer overall among women, with an estimated 65,620 new diagnoses expected in the United States in 2020 [1]. Since the early 1980s, the incidence of uterine cancer among White women in the United States has stayed relatively steady, while rates among Black, Hispanic, and other minority groups have increased, particularly since the late 1990s [2]. Although 75% of patients present with stage I disease and have a favorable prognosis [2], an estimated 12,590 women die of endometrial cancer each year [1]. Furthermore, the 5-year survival rate for women diagnosed with uterine cancer has decreased from 85.2% in 2000 to 81.7% in 2006–2012 [3]. The objective of this article is to review the landmark evidence base that can help guide clinical decision-making in the management of women diagnosed with endometrial cancer.